This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dexverapamil
Accession Number
DB14063
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • (+)-(R)-verapamil
  • (+)-verapamil
  • (R)-(+)-verapamil
  • (R)-verapamil
  • Dexvérapamil
  • Dexverapamilo
  • Dexverapamilum
Categories
UNII
QR5PYD126V
CAS number
38321-02-7
Weight
Average: 454.611
Monoisotopic: 454.283157712
Chemical Formula
C27H38N2O4
InChI Key
SGTNSNPWRIOYBX-HHHXNRCGSA-N
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3/t27-/m1/s1
IUPAC Name
(2R)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES
COC1=CC=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1OC

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AMultidrug resistance protein 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Dexverapamil.
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Dexverapamil.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Dexverapamil.
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Dexverapamil.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Dexverapamil.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Dexverapamil.
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Dexverapamil.
AlclometasoneThe metabolism of Dexverapamil can be decreased when combined with Alclometasone.
AlcuroniumDexverapamil may increase the neuromuscular blocking activities of Alcuronium.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Dexverapamil.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
59223
BindingDB
50338982
ChEBI
77734
ChEMBL
CHEMBL197

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP5.23ALOGPS
logP5.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.95 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity132.65 m3·mol-1ChemAxon
Polarizability51.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Nobili S, Landini I, Giglioni B, Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006 Jul;7(7):861-79. [PubMed:16842217]
  2. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK, Chabner B: Clinical reversal of multidrug resistance. Stem Cells. 1996 Jan;14(1):56-63. doi: 10.1002/stem.140056. [PubMed:8820952]
  3. Wilson WH, Jamis-Dow C, Bryant G, Balis FM, Klecker RW, Bates SE, Chabner BA, Steinberg SM, Kohler DR, Wittes RE: Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol. 1995 Aug;13(8):1985-94. doi: 10.1200/JCO.1995.13.8.1985. [PubMed:7636539]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on June 14, 2018 13:56 / Updated on August 26, 2018 02:07